Elekta

A leader in precision radiation therapy, we are committed to ensuring every patient with cancer has access to the best care possible.

[Elekta @Elekta]

Join us for Elekta’s Capital Markets Day on Wednesday, June 17, where CEO Jakob Just-Bomholt, CFO Klara Eiritz, and members of our leadership team will share insights into our strategy and future direction.

Register to attend: https://t.co/X1cKVhCrqf

[Elekta @Elekta]

Today, we present our Q4 & full year results. It's a strong finish to the year with improved profitability and our strongest cash flow in five years (SEK 1,392 M). With our new operating model in place, we’re focused on near-term profitability and mid-term innovation driven growth. More to come at our Capital Markets Day on June 17. 👉 Read more: https://t.co/COflBtmkQ7

[Elekta @Elekta]

Attending #ISRS2026 in Sydney? Join our Lunch Symposium to explore how innovations in stereotactic radiotherapy are expanding treatment possibilities, including new indications, alternative fractionation approaches, and improved workflow efficiency. Save your spot 👉 https://t.co/RIth8GPOkE

[Elekta @Elekta]

Highlights from #ESTRO26! ☕️
If you missed our Coffee & Connect sessions at the booth, here are a few key insights and perspectives shared by Prof. Dr Chian Gani, Dr. Matthias Lampe, Dr. Hui Khee Looe and Dr. Erwin Wiegman – covering innovation, clinical experience and the future of radiotherapy.

[Elekta @Elekta]

New findings in glioblastoma show how MR‑guided adaptive radiotherapy can reduce treatment volumes by 40% while maintaining outcomes and a 4% marginal failure vs 11% historically. A step forward in delivering precise care and helping protect healthy brain tissue.
👉 Read the full study in The Lancet Oncology: https://t.co/L9rF1TSGxV

*Study by Detsky et al., UNITED trial investigators at Sunnybrook Health Sciences Centre.

[Elekta @Elekta]

A heartfelt thank you to everyone, both near and far, who spent time with us at #ESTRO26. We are grateful for the opportunity to connect in person and look forward to seeing you next year in Milan, Italy!

[Elekta @Elekta]

Which topic has been your key focus at #ESTRO26?

[Elekta @Elekta]

Emerging evidence presented at #ESTRO26 highlights advances in MR-guided adaptive radiotherapy across multiple cancer indications. Read more in today’s press release ➡️ https://t.co/dKV6VUeJb2

[Elekta @Elekta]

The #ESTRO26 exhibit hall is open for one more day! Don’t miss the chance to explore how our adaptive solutions can benefit you, your patients and your clinic. Bonus: it's been said we have the best coffee around. ☕ 🍩

[Elekta @Elekta]

God morgon! 👋 Come by our booth and book a demo! #ESTRO26

[Elekta @Elekta]

The correct answer: Professor Lars Leksell invented the concept of stereotactic radiosurgery in 1951, which is the same year the Leksell Gamma Knife was born.

[Elekta @Elekta]

Innovation has a hometown. Stereotactic radiosurgery was born in Stockholm! #ESTRO26

Do you know what year it all began?

[Elekta @Elekta]

It was a pleasure to connect with customers, colleagues and friends today at #ESTRO26. If you missed us, don't worry, there's still plenty to explore tomorrow at Elekta booth C10:87.

[Elekta @Elekta]

Live from #ESTRO26 with a message from our CEO, Jakob Just-Bomholt.

[Elekta @Elekta]

Discover how adaptive approaches are expanding access to precision treatment and shaping the future of #radiotherapy delivery. Join us today at #ESTRO26 in Stockholm for our Lunch Symposium.

[Elekta @Elekta]

#ESTRO26 is officially underway in Stockholm, Sweden! Over the next few days, follow along to find out how our solutions can help you continue to make a world of difference for your patients and your clinic.

[Elekta @Elekta]

Meet us at #ESTRO26 👋

[Elekta @Elekta]

Discover how adaptive approaches are expanding access to precision treatment and shaping the future of #radiotherapy delivery. Join us at #ESTRO26 in Stockholm for our Lunch Symposium. Register now ➡️ https://t.co/MwKhDQa99v

[Elekta @Elekta]

May is Skin Cancer Awareness Month.
In clinical practice, multiple factors guide treatment decisions, but priorities can vary.
What influences your decision to use brachytherapy for skin cancer?